Compass Therapeutics (CMPX) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NovaBridge Biosciences (NBP) has outperformed Compass Therapeutics (CMPX) over the past year, losing 78.2% versus a loss of 79.8%. Over five years, CMPX leads with a -73.5% price change compared with -98.1% for NBP. Compass Therapeutics is the larger company by market cap ($154.9 million vs $146.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | NBP |
|---|---|---|
| Share price | $0.86 | $1.26 |
| Market cap | $154.88M | $146.16M |
| 1-day change | -4.09% | -2.33% |
| YTD return | -83.99% | -68.34% |
| 1-year return | -79.81% | -78.16% |
| 5-year return | -73.54% | -98.13% |
| EPS (TTM) | $-0.39 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-66.49M | $-46.27M |
| 52-week high | $6.88 | $5.97 |
| 52-week low | $0.822 | $1.26 |
| Distance from 52-week high | -87.50% | -78.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +533.72% | +614.29% |
| Average volume | 4.30M | 390.05K |
| Shares outstanding | 180.09M | 116.00M |
| Employees | 39 | 30 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
CMPX vs NBP FAQ
Which is bigger, Compass Therapeutics or NovaBridge Biosciences?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $154.88M compared with $146.16M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, CMPX or NBP?
NBP returned -78.16% over the past 12 months, compared with -79.81% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.